<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25703" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Nephrogenic Systemic Fibrosis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Shamam</surname>
            <given-names>Younus M.</given-names>
          </name>
          <aff>University of Mosul, College of Medicine , Mosul Iraq</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hashmi</surname>
            <given-names>Muhammad F.</given-names>
          </name>
          <aff>National Health Service</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>De Jesus</surname>
            <given-names>Orlando</given-names>
          </name>
          <aff>University of Puerto Rico, Medical Sciences Campus, Neurosurgery Section</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Younus Shamam declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Muhammad Hashmi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Orlando De Jesus declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>1</day>
          <month>11</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25703.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Nephrogenic systemic fibrosis (NSF) is a rare yet serious fibrosing disorder primarily affecting patients with impaired renal function who have been exposed to gadolinium-based contrast agents during magnetic resonance imaging. This progressive condition involves fibrosis of the skin and connective tissues, leading to painful skin thickening, joint contractures, and decreased mobility. NSF may extend beyond the skin, involving internal organs such as the liver, lungs, heart, and muscles, and potentially causing severe disability or death. Early recognition of NSF and preventive measures, particularly avoiding certain gadolinium agents in at-risk patients, is critical for reducing its incidence and associated morbidity.</p>
        <p>In this course, healthcare professionals gain comprehensive knowledge about NSF's pathophysiology, risk factors, and clinical presentation. Participants learn to assess patients' risk before imaging and recognize NSF symptoms for prompt intervention. The course emphasizes an interprofessional approach, promoting collaboration between radiologists, nephrologists, dermatologists, and primary care providers to ensure safe imaging practices and effective, multidisciplinary management for at-risk patients. Through enhanced competence in identifying and preventing NSF, clinicians contribute to more effective, patient-centered care, ultimately reducing complications and improving patient outcomes.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Differentiate&#x000a0;nephrogenic systemic fibrosis from other fibrosing conditions that may present similarly, such as systemic sclerosis or scleromyxedema.</p></list-item><list-item><p>Compare the characteristics and grading systems of different gadolinium-containing agents, selecting those which are safest for those with advanced renal failure.&#x000a0;</p></list-item><list-item><p>Implement therapeutic options available for patients who develop nephrogenic systemic fibrosis.</p></list-item><list-item><p>Collaborate among an interprofessional team about strategies to improve care coordination and communication for patients at risk of developing nephrogenic systemic fibrosis.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25703&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25703">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-25703.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Nephrogenic systemic fibrosis (NSF) is a progressive multiorgan fibrosing condition caused by exposure to gadolinium-based contrast agents&#x000a0;(GBCAs) used for magnetic resonance imaging (MRI) in the setting of low glomerular filtration rate (GFR).<xref ref-type="bibr" rid="article-25703.r1">[1]</xref> This condition is characterized by thickening of the skin and subcutaneous tissue in addition to systemic manifestations. The clinical features may also involve skeletal muscle and any fibrous tissue in the body, including the internal organs such as the liver, heart, and lungs.<xref ref-type="bibr" rid="article-25703.r2">[2]</xref><xref ref-type="bibr" rid="article-25703.r3">[3]</xref><xref ref-type="bibr" rid="article-25703.r4">[4]</xref>&#x000a0;NSF is a clinically highly variable condition. Some patients may have only mild effects on the skin, but many patients develop significant debility. In some patients, the disease may be lethal.<xref ref-type="bibr" rid="article-25703.r2">[2]</xref></p>
        <p>The condition was first described in 2000 when several physicians across the United States (US) noted patients with a scleroderma-type illness, and the association with GBCA administration in the setting of renal failure was solidified as more cases were presented.<xref ref-type="bibr" rid="article-25703.r1">[1]</xref><xref ref-type="bibr" rid="article-25703.r5">[5]</xref><xref ref-type="bibr" rid="article-25703.r6">[6]</xref>&#x000a0;NSF occurs in patients with acute or severe chronic renal failure, usually stage 4 or 5 chronic kidney disease (CKD), but it has also been described in patients with stage 3 CKD.<xref ref-type="bibr" rid="article-25703.r7">[7]</xref>&#x000a0;The condition was initially called&#x000a0;nephrogenic fibrosing dermopathy due to the cutaneous manifestation. Still, the terminology changed to&#x000a0;gadolinium-induced fibrosis or NSF as more systemic manifestations came to light.<xref ref-type="bibr" rid="article-25703.r1">[1]</xref><xref ref-type="bibr" rid="article-25703.r8">[8]</xref><xref ref-type="bibr" rid="article-25703.r9">[9]</xref>&#x000a0;Fortunately, the incidence of this condition has significantly decreased since 2007, when the US Food and Drug Administration placed a black box warning on using gadolinium-containing products in patients with severely decreased GFR.&#x000a0;However, 32 cases were reported annually in 2019 and 2020.<xref ref-type="bibr" rid="article-25703.r10">[10]</xref>&#x000a0;&#x000a0;</p>
      </sec>
      <sec id="article-25703.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Gadolinium is a paramagnetic element that enhances soft tissue and is used to visualize a variety of body compositions. Gadolinium (Gd) is toxic to humans but can be combined with organic chelates to prevent the release of Gd ions; this is the basis of GBCAs. Gd can be classified into linear versus cyclic and ionic versus nonionic (see <bold>Table.</bold> Gd Types). Linear molecules bind Gd less tightly and are at higher risk of causing NSF.<xref ref-type="bibr" rid="article-25703.r10">[10]</xref>&#x000a0;</p>
        <table-wrap id="article-25703.table0" position="float" orientation="portrait">
          <caption>
            <title>Table. Gd Types</title>
          </caption>
          <table style="width: 600px; float: left;" border="1" cellspacing="1" cellpadding="2">
            <tbody>
              <tr style="height: 13.48px;">
                <td style="height: 13.48px; width: 47.2667px; text-align: left;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="height: 13.48px; width: 310.558px;" rowspan="1" colspan="1">
<bold>Ionic</bold>
</td>
                <td style="height: 13.48px; width: 177.775px;" rowspan="1" colspan="1">
<bold>Nonionic</bold>
</td>
              </tr>
              <tr style="height: 13px;">
                <td style="height: 13px; width: 47.2667px; text-align: left;" rowspan="1" colspan="1">
<bold>Linear</bold>
</td>
                <td style="height: 13px; width: 310.558px;" rowspan="1" colspan="1">Gadopentetate dimeglumine, gadobenate dimeglumine, gadoxetate disodium</td>
                <td style="height: 13px; width: 177.775px;" rowspan="1" colspan="1">Gadodiamide, gadoversetamide</td>
              </tr>
              <tr style="height: 9px;">
                <td style="height: 9px; width: 47.2667px; text-align: left;" rowspan="1" colspan="1">
<bold>Cyclic</bold>
</td>
                <td style="height: 9px; width: 310.558px;" rowspan="1" colspan="1">Gadoterate meglumine</td>
                <td style="height: 9px; width: 177.775px;" rowspan="1" colspan="1">Gadoteridol, gadobutrol</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>Each category has a different risk of NSF as classified by the&#x000a0;Committee for Medicinal Products for Human Use&#x000a0;as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>High-risk includes gadopentetate dimeglumine (Magnevist), gadodiamide (Omniscan), and gadoversetamide (OptiMARK).</p>
          </list-item>
          <list-item>
            <p>Medium-risk includes gadoxetate disodium (Primovist) and gadobenate dimeglumine (MultiHance). Although gadoxetate disodium is a linear molecule, it is excreted 50% by the kidney and 50% through bile.</p>
          </list-item>
          <list-item>
            <p>Low-risk includes gadobutrol (Gadovist),&#x000a0; gadoteridol (ProHance), and gadoterate meglumine (Dotarem).</p>
          </list-item>
        </list>
        <p>The American College of Radiology also has a similar classification system of 3 groups, with group 1 being the highest risk and group 3, the lowest:</p>
        <list list-type="bullet">
          <list-item>
            <p>Group 1: Gadodiamide, gadoversetamide, gadopentetate dimeglumin</p>
          </list-item>
          <list-item>
            <p>Group 2: Gadobenate dimeglumine, gadobutrol, gadoteric acid, gadoterido</p>
          </list-item>
          <list-item>
            <p>Group 3: Gadoxetate disodium&#x000a0;<xref ref-type="bibr" rid="article-25703.r11">[11]</xref></p>
          </list-item>
        </list>
        <p>Other relevant characteristics of GBCA include thermodynamic stability and relaxivity. Higher relaxivity allows endogenous metals such as iron, copper, and zinc to displace the Gd. The Gd molecule can bind with endogenous ions such as carbonate (CO<sub>3</sub><sup>2&#x02212;</sup>) and phosphate (PO<sub>4</sub><sup>3&#x02212;</sup>), forming insoluble compounds that deposit in tissues.<xref ref-type="bibr" rid="article-25703.r11">[11]</xref> Gd is cleared almost entirely by the kidneys. The Gd is cleared within 90 minutes in patients with normal renal function. However, in patients with impaired kidney function, the half-life can be up to 30 hours, allowing Gd to dissociate and form insoluble compounds. Using hemodialysis immediately after GBCA decreases the risk of NSF but does not eliminate it, as not all the GBCA is cleared via hemodialysis.<xref ref-type="bibr" rid="article-25703.r10">[10]</xref>&#x000a0;</p>
        <p>Gd has also been shown to be immunogenic in vitro, activating toll-like receptors, macrophages, and dendritic cells.<xref ref-type="bibr" rid="article-25703.r11">[11]</xref>&#x000a0;This initiates a vicious fibrotic cycle of transforming growth factor-beta 1 production and dendritic cell maturation, resulting in excessive collagen deposition in&#x000a0;the extracellular matrix and soft tissues.<xref ref-type="bibr" rid="article-25703.r7">[7]</xref>&#x000a0;Activation of dermal fibroblasts is a key component in the pathogenesis of NSF. The dermal fibroblasts synthesize excess glycosaminoglycans, particularly hyaluronan, which is partially responsible for the characteristic skin thickening.<xref ref-type="bibr" rid="article-25703.r12">[12]</xref>&#x000a0;Factors contributing to NSF include total gadolinium exposure, hypercalcemia, hyperphosphatemia,&#x000a0;high-dose erythropoietin therapy, hepatorenal syndrome, immunosuppression, and vasculopathy. Results from one notable study showed that the risk of NSF was increased by 25 times when infection was present.<xref ref-type="bibr" rid="article-25703.r13">[13]</xref></p>
      </sec>
      <sec id="article-25703.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Nephrogenic systemic fibrosis is an iatrogenic disease first identified in 2000. According to a report by the FDA, about 4.5 million Americans are exposed to GBCAs annually.<xref ref-type="bibr" rid="article-25703.r14">[14]</xref>&#x000a0; Until 2019, the FDA reported 3094 cases of NSF, including 742 deaths and 2922 serious cases. Of note, the US has the second-highest MRI utilization rate after Germany.<xref ref-type="bibr" rid="article-25703.r15">[15]</xref>&#x000a0;As noted above, 32 cases were reported in each of 2019 and 2020.&#x000a0;</p>
        <p>NSF affects any ethnicity, sex, or age.<xref ref-type="bibr" rid="article-25703.r1">[1]</xref><xref ref-type="bibr" rid="article-25703.r8">[8]</xref><xref ref-type="bibr" rid="article-25703.r16">[16]</xref>&#x000a0;The&#x000a0;risk of developing NSF depends on the amount of residual renal function and the type of GBCA used.&#x000a0;The amount of the initial dose and the&#x000a0;cumulative dose of GBCA can also increase the risk.<xref ref-type="bibr" rid="article-25703.r16">[16]</xref>&#x000a0;When the high-risk group 1 GBCAs were used, the estimated incidence was 36.5 cases per 100,000 gadolinium-enhanced MRI examinations.<xref ref-type="bibr" rid="article-25703.r17">[17]</xref>&#x000a0;Systematic reviews have found that no patients developed biopsy-proven NSF&#x000a0;among patients receiving group 2 or 3 GBCAs; the estimated risk of NSF when using group 2 or 3 GBCAs is less than 0.07%.<xref ref-type="bibr" rid="article-25703.r18">[18]</xref><xref ref-type="bibr" rid="article-25703.r19">[19]</xref>&#x000a0;&#x000a0;&#x000a0;</p>
      </sec>
      <sec id="article-25703.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>
<bold>Various Hypotheses Concerning Underlying Pathogenic Mechanisms</bold>
</p>
        <p>The following discussion is essential for historical reasons, as the understanding of NSF has&#x000a0;significantly evolved.</p>
        <list list-type="bullet">
          <list-item>
            <p>In 2002, a group proposed that hemodialysis patients with hepatitis C would be more at risk of developing NSF due to high levels of fibroblast growth factor or TGF-&#x003b2;1.<xref ref-type="bibr" rid="article-25703.r20">[20]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>In 2003, another group put forward 2 theories to explain the pathogenesis of NSF. First, they observed that anticardiolipin or antiphospholipid antibodies had a significant role in the development of NSF. Second, they believed that&#x000a0;edema coupled with the suppressed immune system in patients with antiphospholipid antibodies&#x000a0;triggers a physiologic response, leading to the proliferation of fibroblast-like cells and mucin deposition in the dermis.<xref ref-type="bibr" rid="article-25703.r21">[21]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>In 2004, the histopathology of NSF was studied, and it was found that the fibrotic process of NSF was not limited to the dermis. Instead, it extended to the subcutaneous tissues, fascia, skeletal muscles, lungs, and myocardium. The skin contained large cluster of differentiation (CD)68/factor 13a&#x000a0;dendritic cells and an abundance of TGF-&#x003b2;1.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The prevailing theory is that Gd exposure is prolonged in patients with renal disease, allowing the Gd to dissociate from its organic chelators and bind with calcium, phosphate, and other endogenous compounds to deposit in the skin and tissues. This sets off a fibrotic reaction involving the proliferation of fibroblasts in the dermis and the replacement of normal tissue with thickened collagen and extracellular matrix hyaluronan. Deposition also occurs in other tissues and leads to multi-organ involvement.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Abnormal calcium and phosphorus metabolism has also been found in patients who develop NSF compared to patients with a similar estimated glomerular filtration rate who did not develop NSF, and calcium and phosphorus deposits have also been found in the gadolinium-containing deposits of NSF.<xref ref-type="bibr" rid="article-25703.r22">[22]</xref>&#x000a0;Traumatic calcinosis cutis, osseous metaplasia, calciphylaxis, and metastatic calcification have also been observed in dialysis patients with NSF.<xref ref-type="bibr" rid="article-25703.r23">[23]</xref><xref ref-type="bibr" rid="article-25703.r24">[24]</xref>&#x000a0;A variant of&#x000a0;NSF has been referred to as&#x000a0;a pathology of dysregulated matrix remodeling, and it appears to involve osteoclast-like giant cells.&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25703.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Findings on skin biopsy will evolve. Initially, gadolinium may be present, but the amount of Gd does not correlate with disease severity. Most notable is collagen deposition in thick bundles, mucin, and widened subcutaneous septae. A significant increase in cellularity is also noted. These cells are spindle-shaped fibroblasts, fibroblast-like,&#x000a0;or polygonal epithelioid fibroblasts.&#x000a0;The abundant spindle-shaped cells often express type 1 procollagen and CD34.<xref ref-type="bibr" rid="article-25703.r25">[25]</xref><xref ref-type="bibr" rid="article-25703.r26">[26]</xref><xref ref-type="bibr" rid="article-25703.r27">[27]</xref><xref ref-type="bibr" rid="article-25703.r28">[28]</xref>&#x000a0;</p>
        <p>Electron microscopy may show increased elastic fibers as opposed to dendritic cell processes. Inflammation is usually absent.<xref ref-type="bibr" rid="article-25703.r28">[28]</xref>&#x000a0;Over time, the collagen bundles thicken, and fibrocytes and mucin become "sandwiched" between these bundles. The dermis becomes involved with increased fibrocytes, collagen, mucin, and elastic fibers. The fibrous tissue creates a microlobular architecture; calcification has also been described.<xref ref-type="bibr" rid="article-25703.r27">[27]</xref></p>
      </sec>
      <sec id="article-25703.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Clinical manifestations of nephrogenic systemic fibrosis (NSF) may occur days or even years after GBCA exposure but usually present within 2 to 10 weeks.&#x000a0;One case report describes a patient on hemodialysis who developed NSF 10 years after his last Gd exposure.<xref ref-type="bibr" rid="article-25703.r16">[16]</xref><xref ref-type="bibr" rid="article-25703.r29">[29]</xref>&#x000a0;All patients will have a history of renal&#x000a0;impairment of varying severity and duration and gadolinium exposure. Many patients are on renal replacement therapy&#x02014;namely&#x000a0;hemodialysis, peritoneal dialysis, or renal transplantation. However, patients not on renal replacement therapy who have residual renal function can also develop nephrogenic systemic fibrosis.<xref ref-type="bibr" rid="article-25703.r1">[1]</xref>&#x000a0;</p>
        <p>
<bold>Dermatologic</bold>
</p>
        <p>One of the first and most common manifestations is acute thickening and hardening of the skin. The first noted cases were described as "scleroderma-like."&#x000a0;This condition may develop quickly or slowly. Pruritis and burning sensations are the most common symptoms. Patients may describe tightening or thickening of the skin or that their skin looks shinier. The skin is often lumpy with nodular thickening and indurated plaques with a fluctuating leading edge.</p>
        <p>The affected areas have been described as hard and "woody." The plaques are usually symmetrical and start on the hands or feet and progress medially (in contrast, scleroderma usually starts on the trunk and progresses distally). The Rodnan skin thickness score can measure skin thickness, and skin is often discolored to a brawny color.&#x000a0;The skin can have a&#x000a0;<italic toggle="yes">peau d'orange</italic>&#x000a0;appearance (ie, induration overlying hard subcutaneous tissue).&#x000a0;The face is almost always spared.<xref ref-type="bibr" rid="article-25703.r1">[1]</xref><xref ref-type="bibr" rid="article-25703.r12">[12]</xref>&#x000a0;</p>
        <p>Major criteria include patterned plaques, joint contractures, or pronounced induration (<italic toggle="yes">peau d&#x02019; orange),</italic>&#x000a0;while minor criteria consist of linear banding, superficial plaques, dermal papules, and scleral plaques.<xref ref-type="bibr" rid="article-25703.r28">[28]</xref>&#x000a0;Later manifestations of NSF may evolve into wrinkled, redundant skin (ie, cutis laxa) with symmetrical hair loss and epidermal atrophy. One biopsy of this skin showed collagen thickening and elastolysis in the dermis.<xref ref-type="bibr" rid="article-25703.r27">[27]</xref></p>
        <p>
<bold>Musculoskeletal</bold>
</p>
        <p>NSF has also been observed to involve joints and skeletal muscle.<xref ref-type="bibr" rid="article-25703.r30">[30]</xref>&#x000a0;Joint involvement usually results in disability and contractures. The palms may have superficial flesh-colored or pink macules or papules, which can coalesce into scaly plaques. Hand and foot blistering has also been noted.<xref ref-type="bibr" rid="article-25703.r12">[12]</xref>&#x000a0;The joints under the affected skin often become fibrosed, causing severe flexion contractures. Loss of ambulation is common.<xref ref-type="bibr" rid="article-25703.r30">[30]</xref><xref ref-type="bibr" rid="article-25703.r31">[31]</xref>&#x000a0;</p>
        <p>
<bold>Eyes/Cranial</bold>
</p>
        <p>Although the face is usually spared, yellow scleral plaques have been reported and are a minor criterion. Vision is not usually compromised. The dura mater can also be involved.<xref ref-type="bibr" rid="article-25703.r1">[1]</xref><xref ref-type="bibr" rid="article-25703.r12">[12]</xref></p>
        <p>
<bold>Renal&#x000a0;</bold>
</p>
        <p>The fibrosis may also involve the renal tubules, although this has not been described histologically.<xref ref-type="bibr" rid="article-25703.r1">[1]</xref>&#x000a0;</p>
        <p>
<bold>Cardiopulmonary</bold>
</p>
        <p>Cardiac involvement can lead to cardiomyopathy or pulmonary hypertension. Calcification may occur in the coronary arteries or along the cardiac valves.<xref ref-type="bibr" rid="article-25703.r27">[27]</xref>&#x000a0;The mortality rate increases if the lungs are affected, particularly if the diaphragm is involved.<xref ref-type="bibr" rid="article-25703.r8">[8]</xref><xref ref-type="bibr" rid="article-25703.r12">[12]</xref></p>
      </sec>
      <sec id="article-25703.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>NSF is a clinicopathologic diagnosis that can be made by the history and physical and supported by a skin biopsy. The biopsy findings are described in the Histology section.&#x000a0;A deep punch skin biopsy should be performed, including the dermis, subcutaneous fat, and fascia. Care should be taken not to introduce metal contamination from the biopsy device or handle the specimen (eg, forceps).<xref ref-type="bibr" rid="article-25703.r32">[32]</xref></p>
        <p>Rarely, some patients with NSF are found to have the following in their blood:</p>
        <list list-type="bullet">
          <list-item>
            <p>Peripheral eosinophilia</p>
          </list-item>
          <list-item>
            <p>Antinuclear antibodies</p>
          </list-item>
          <list-item>
            <p>Anticardiolipin or antiphospholipid antibodies</p>
          </list-item>
          <list-item>
            <p>Hypercoagulability</p>
          </list-item>
        </list>
        <p>Nerve conduction abnormalities have been reported in some patients. To evaluate for cardiac involvement, an electrocardiogram should also be performed.</p>
      </sec>
      <sec id="article-25703.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>To date, there are no proven treatments that cure nephrogenic systemic fibrosis, and most often, combination therapy is used. Restoration of renal function, if feasible, is essential to prevent further progression as it appears to slow or hold the progression.<xref ref-type="bibr" rid="article-25703.r16">[16]</xref><xref ref-type="bibr" rid="article-25703.r33">[33]</xref><xref ref-type="bibr" rid="article-25703.r34">[34]</xref>&#x000a0;In 2005, photodynamic therapy was reported to be a successful treatment option for NSF and has been used since that time with variable success. Ultraviolet (UV) therapy includes UVA, UVB, and UVA with psoralen.<xref ref-type="bibr" rid="article-25703.r34">[34]</xref><xref ref-type="bibr" rid="article-25703.r35">[35]</xref><xref ref-type="bibr" rid="article-25703.r36">[36]</xref><xref ref-type="bibr" rid="article-25703.r37">[37]</xref></p>
        <p>Extracorporeal photopheresis (ECP)&#x000a0;is a promising treatment option for nephrogenic systemic fibrosis. In this procedure, blood is drawn, and the white blood cells are separated and treated with the drug psoralen (8-methoxypsoralen) and UV light. The treated lymphocytes are then infused back into the patient. This is anti-inflammatory without being immunosuppressive. NSF is considered a class 3 indication for ECP&#x02014;"inconclusive evidence."<xref ref-type="bibr" rid="article-25703.r34">[34]</xref><xref ref-type="bibr" rid="article-25703.r38">[38]</xref><xref ref-type="bibr" rid="article-25703.r39">[39]</xref></p>
        <p>There have been anecdotal reports of improvement in NSF lesions after treatment with the following agents:</p>
        <list list-type="bullet">
          <list-item>
            <p>Methotrexate</p>
          </list-item>
          <list-item>
            <p>Rapamycin</p>
          </list-item>
          <list-item>
            <p>Sodium thiosulfate</p>
          </list-item>
          <list-item>
            <p>Pentoxifylline</p>
          </list-item>
          <list-item>
            <p>Glucocorticoids</p>
          </list-item>
          <list-item>
            <p>Imatinib</p>
          </list-item>
          <list-item>
            <p>Thalidomide</p>
          </list-item>
          <list-item>
            <p>Interferon alpha</p>
          </list-item>
          <list-item>
            <p>Topical calcipotriene</p>
          </list-item>
          <list-item>
            <p>Topical betamethasone</p>
          </list-item>
          <list-item>
            <p>Plasmapheresis</p>
          </list-item>
          <list-item>
            <p>Intravenous immunoglobulin <xref ref-type="bibr" rid="article-25703.r1">[1]</xref><xref ref-type="bibr" rid="article-25703.r16">[16]</xref><xref ref-type="bibr" rid="article-25703.r40">[40]</xref><xref ref-type="bibr" rid="article-25703.r41">[41]</xref><xref ref-type="bibr" rid="article-25703.r42">[42]</xref><xref ref-type="bibr" rid="article-25703.r43">[43]</xref><xref ref-type="bibr" rid="article-25703.r44">[44]</xref><xref ref-type="bibr" rid="article-25703.r45">[45]</xref></p>
          </list-item>
        </list>
        <p>Narcotic analgesics may be required to control pain secondary to contractures.&#x000a0;Physical therapy is an important part of the treatment to maintain and improve&#x000a0;joint motion and reduce contractures.<xref ref-type="bibr" rid="article-25703.r1">[1]</xref> Renal transplantation may also improve symptoms.<xref ref-type="bibr" rid="article-25703.r46">[46]</xref><xref ref-type="bibr" rid="article-25703.r47">[47]</xref><xref ref-type="bibr" rid="article-25703.r48">[48]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-25703.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Nephrogenic systemic fibrosis diagnosis relies on excluding the other differential diagnoses; thus, healthcare professionals should be aware of these differentials. The following diseases encompass the most likely differential diagnosis:</p>
        <list list-type="bullet">
          <list-item>
            <p>&#x003b2;-microglobulin amyloidosis</p>
          </list-item>
          <list-item>
            <p>Borreliosis</p>
          </list-item>
          <list-item>
            <p>Calciphylaxis</p>
          </list-item>
          <list-item>
            <p>Chronic graft versus host disease</p>
          </list-item>
          <list-item>
            <p>Drug-induced fibrosis</p>
          </list-item>
          <list-item>
            <p>Dermatofibrosarcoma protuberans</p>
          </list-item>
          <list-item>
            <p>Early cellulitis</p>
          </list-item>
          <list-item>
            <p>Early panniculitis</p>
          </list-item>
          <list-item>
            <p>Eosinophilic fasciitis</p>
          </list-item>
          <list-item>
            <p>Fibroblastic rheumatism</p>
          </list-item>
          <list-item>
            <p>Lipodermatosclerosis</p>
          </list-item>
          <list-item>
            <p>Radiation-induced fibrosis</p>
          </list-item>
          <list-item>
            <p>Scleroderma</p>
          </list-item>
          <list-item>
            <p>Scleromyxedema</p>
          </list-item>
          <list-item>
            <p>Phenylketonuria</p>
          </list-item>
          <list-item>
            <p>Porphyria cutanea tarda</p>
          </list-item>
          <list-item>
            <p>Superficial fibromatosis&#x000a0;<xref ref-type="bibr" rid="article-25703.r1">[1]</xref></p>
          </list-item>
        </list>
        <p>Noting the history of GBCA&#x000a0;exposure during the MRI examination will favor&#x000a0;NSF among the differential diagnosis.<xref ref-type="bibr" rid="article-25703.r49">[49]</xref>&#x000a0;Among the differential diagnoses, only &#x003b2;2-microglobulin amyloidosis occurs exclusively in individuals with advanced renal disease; however, it usually&#x000a0;affects the shoulders, volar wrists, and tongue.<xref ref-type="bibr" rid="article-25703.r1">[1]</xref>&#x000a0;As noted above, in contrast to NSF, scleroderma usually starts at the trunk and moves peripherally, while scleromyxedema usually involves the head and neck (the face is not involved in NSF).<xref ref-type="bibr" rid="article-25703.r27">[27]</xref></p>
      </sec>
      <sec id="article-25703.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Nephrogenic systemic fibrosis is considered a debilitating, progressive disease. This condition causes visceral and cutaneous fibrosis in patients with severe renal insufficiency exposed to&#x000a0;GBCAs. Although skin changes associated with NSF may be improved after the restoration of kidney function, especially after recovery from acute kidney injury, this condition does not usually regress spontaneously and&#x000a0;almost always progresses relentlessly. The high mortality rate does not come from the cutaneous lesions but rather from visceral fibrosis, particularly in the cardiac and respiratory systems.<xref ref-type="bibr" rid="article-25703.r50">[50]</xref></p>
        <p>One group observed that 24-month mortality following examination was 48% in patients with skin changes and 20% in the cases where skin changes were absent.<xref ref-type="bibr" rid="article-25703.r50">[50]</xref>&#x000a0;Within a few weeks of disease onset, most patients became wheelchair-bound&#x000a0;due to contractures; patients can also experience flexion contractures if the condition involves a joint. Mortality in many patients has been attributed to&#x000a0;falls and other complications due to limited mobility. In addition, many patients have reported causalgia and maddening pruritus.&#x000a0;</p>
      </sec>
      <sec id="article-25703.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Nephrogenic systemic fibrosis complicates the already existing kidney disease. The complications of NSF include:</p>
        <list list-type="bullet">
          <list-item>
            <p>The most debilitating NSF sequelae are the fibrosis of visceral organs such as the heart, lungs, renal tubules, and skeletal muscles. Although visceral fibrosis is often asymptomatic, it may&#x000a0;contribute to the development of pulmonary hypertension, cardiomyopathy, and skeletal muscle weakness.</p>
          </list-item>
          <list-item>
            <p>Patients with NSF may&#x000a0;experience blood vessel thrombosis; as&#x000a0;the disease progresses, these patients may&#x000a0;develop significant hypotension, affecting their ability to tolerate the hemodialysis.<xref ref-type="bibr" rid="article-25703.r51">[51]</xref></p>
          </list-item>
          <list-item>
            <p>Flexion contractures may lead to wheelchair dependence within weeks in many patients.</p>
          </list-item>
          <list-item>
            <p>Falls are common in these patients, and fractures can also occur.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25703.s13" sec-type="Consultations">
        <title>Consultations</title>
        <p>The diagnosis and management of NSF need a multidisciplinary team. The following specialties work as a team for NSF management:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Dermatology</p>
          </list-item>
          <list-item>
            <p>Nephrology</p>
          </list-item>
          <list-item>
            <p>Radiology</p>
          </list-item>
          <list-item>
            <p>Pulmonology</p>
          </list-item>
          <list-item>
            <p>Histopathology</p>
          </list-item>
          <list-item>
            <p>Physical medicine and rehabilitation</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25703.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Since this disease is caused by GBCA exposure in patients with severe renal impairment, optimization of renal function is pivotal. Patients with this condition should be informed that no proven treatments can cure NSF, and the current therapies can only relieve some symptoms. However, if the disease progresses and visceral fibrosis develops, medication adherence may improve patients' quality of life.<xref ref-type="bibr" rid="article-25703.r7">[7]</xref></p>
        <p>For patients with severe kidney disease,&#x000a0;healthcare professionals should&#x000a0;discuss and guide patients on the potential risks of GBCAs. Clinicians should discuss the MRI study's risks and benefits over the alternative use of a contrast-enhanced computed tomography (CT) scan, which can potentially produce a loss of residual renal function and precipitate dialysis initiation.<xref ref-type="bibr" rid="article-25703.r19">[19]</xref><xref ref-type="bibr" rid="article-25703.r52">[52]</xref>&#x000a0;Group 2 or 3 GBCAs may be safer than a CT scan with intravenous contrast in patients with stage 4 or 5 chronic kidney disease who still have residual function, as the contrast may eliminate the remaining renal function.<xref ref-type="bibr" rid="article-25703.r53">[53]</xref>&#x000a0;Those patients who have received group 1 GBCAs in the past should be aware of their exposure, as effects can be cumulative.<xref ref-type="bibr" rid="article-25703.r52">[52]</xref></p>
      </sec>
      <sec id="article-25703.s15" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Other important information to note includes the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>The incidence rate of NSF has been drastically reduced since regulatory authorities like the FDA, American College of Radiology, and the European Society of Urogenital Radiology implemented precautionary guidelines advising radiologists to avoid high-risk GBCAs if the patient has severe renal insufficiency.</p>
          </list-item>
          <list-item>
            <p>The chelate of GBCAs is categorized into different groups based on the risk of NSF. In general, molecules bound to a cyclic chelate structure are more stable than those that are bound to a linear chelate (except gadoxetate disodium/Primovist, which, although a linear molecule, is excreted 50% by the kidney and 50% through bile.)</p>
          </list-item>
          <list-item>
            <p>The lowest possible dose of GBCA to obtain the&#x000a0;essential clinical information should be used.</p>
          </list-item>
          <list-item>
            <p>Further doses of GBCA should be delayed several days to a week or avoided if possible.</p>
          </list-item>
          <list-item>
            <p>The diagnostic benefit of GBCAs in the imaging study must be weighed cautiously against the significant risk of developing this debilitating disease.</p>
          </list-item>
          <list-item>
            <p>There is no prophylactic agent that prevents the development of NSF aside from choosing a class 2/3 Gd agent.</p>
          </list-item>
          <list-item>
            <p>High-risk GBCAs (group I) are contraindicated for patients with&#x000a0;acute kidney injury or severe chronic kidney disease.</p>
          </list-item>
          <list-item>
            <p>Early hemodialysis following the GBCA is recommended in patients with chronic hemodialysis, but it does not remove all the contrast medium.</p>
          </list-item>
          <list-item>
            <p>Skin thickening causes significant morbidity in patients related to pain, pruritus, and flexion contractures.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Visceral fibrosis can lead to significant mortality.</p>
          </list-item>
          <list-item>
            <p>No treatments have been proven to reverse the changes of NSF, but UV light therapy and extracorporeal photopheresis are effective in case reports.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25703.s16" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>NSF occurs in patients with renal failure who are exposed to gadolinium. Managing this disease requires the collaboration of the entire healthcare team. The radiologist should avoid high-risk GBCAs in patients with renal failure. The primary clinician should be aware of this disease in patients presenting with symptoms after exposure to GBCAs. After confirming the diagnosis, nurses, pharmacists, and physical therapists are essential for better health outcomes. Dermatologists and dermatopathologists are vital to obtaining and interpreting skin biopsy results. Dermatologists and hematologists/oncologists often administer the variable therapeutic options available.&#x000a0;</p>
        <p>The American College of Radiology recommends screening patients by identifying risk factors for compromised renal function (aged 60 and older, hypertension, diabetes mellitus, dialysis, kidney surgery, kidney transplant, kidney cancer, or single kidney). If the patient presents with 1 of the risk factors, obtaining serum creatinine before GBCA administration is warranted.&#x000a0;According to the European Society of Urogenital Radiology, patient assessment is based on the type of GBCA used. If a high-risk GBCA is to be used, serum creatinine and clinical assessment before contrast medium administration must be performed. For intermediate and low-risk GBCAs, a questionnaire assessment of the renal function is sufficient.</p>
        <p>A strategic approach is equally crucial, involving evidence-based strategies to optimize treatment plans and minimize&#x000a0;adverse events. Ethical considerations must guide decision-making, ensuring informed consent and respecting patient autonomy in treatment choices, especially considering that NSF is iatrogenic and avoidable. Each healthcare professional must know their responsibilities and contribute their unique expertise to the patient's care plan, fostering a multidisciplinary approach.</p>
        <p>Effective interprofessional communication is paramount, allowing seamless information exchange and collaborative decision-making among the team members. Care coordination plays a pivotal role in ensuring that the patient's journey from diagnosis to treatment and follow-up is well-managed, minimizing errors and enhancing patient safety. By embracing these principles of skill, strategy, ethics, responsibilities, interprofessional communication, and care coordination, healthcare professionals can deliver patient-centered care, ultimately improving patient outcomes and enhancing team performance in the management of nephrogenic systemic fibrosis.</p>
      </sec>
      <sec id="article-25703.s17">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25703&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25703">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/medications/nephrogenic-systemic-fibrosis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=25703">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25703/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25703">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-25703.s18">
        <title>References</title>
        <ref id="article-25703.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Todd</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Kay</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Gadolinium-Induced Fibrosis.</article-title>
            <source>Annu Rev Med</source>
            <year>2016</year>
            <volume>67</volume>
            <fpage>273</fpage>
            <page-range>273-91</page-range>
            <pub-id pub-id-type="pmid">26768242</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25703.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Malikova</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Nephrogenic systemic fibrosis: the end of the story?</article-title>
            <source>Quant Imaging Med Surg</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>9</volume>
            <issue>8</issue>
            <fpage>1470</fpage>
            <page-range>1470-1474</page-range>
            <pub-id pub-id-type="pmid">31559176</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25703.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kitajima</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Maeda</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Watanabe</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ueno</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sugimura</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Recent topics related to nephrogenic systemic fibrosis associated with gadolinium-based contrast agents.</article-title>
            <source>Int J Urol</source>
            <year>2012</year>
            <month>Sep</month>
            <volume>19</volume>
            <issue>9</issue>
            <fpage>806</fpage>
            <page-range>806-11</page-range>
            <pub-id pub-id-type="pmid">22571387</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25703.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mathur</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Weinreb</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Gadolinium Deposition and Nephrogenic Systemic Fibrosis: A Radiologist's Primer.</article-title>
            <source>Radiographics</source>
            <year>2020</year>
            <season>Jan-Feb</season>
            <volume>40</volume>
            <issue>1</issue>
            <fpage>153</fpage>
            <page-range>153-162</page-range>
            <pub-id pub-id-type="pmid">31809230</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25703.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cowper</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Su</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Bhawan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Robin</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>LeBoit</surname>
                <given-names>PE</given-names>
              </name>
            </person-group>
            <article-title>Nephrogenic fibrosing dermopathy.</article-title>
            <source>Am J Dermatopathol</source>
            <year>2001</year>
            <month>Oct</month>
            <volume>23</volume>
            <issue>5</issue>
            <fpage>383</fpage>
            <page-range>383-93</page-range>
            <pub-id pub-id-type="pmid">11801769</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25703.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cowper</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Robin</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Steinberg</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Su</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>LeBoit</surname>
                <given-names>PE</given-names>
              </name>
            </person-group>
            <article-title>Scleromyxoedema-like cutaneous diseases in renal-dialysis patients.</article-title>
            <source>Lancet</source>
            <year>2000</year>
            <month>Sep</month>
            <day>16</day>
            <volume>356</volume>
            <issue>9234</issue>
            <fpage>1000</fpage>
            <page-range>1000-1</page-range>
            <pub-id pub-id-type="pmid">11041404</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25703.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lim</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Bang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ko</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Seo</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Jung</surname>
                <given-names>WY</given-names>
              </name>
              <name>
                <surname>Yi</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>MY</given-names>
              </name>
            </person-group>
            <article-title>Late Onset Nephrogenic Systemic Fibrosis in a Patient with Stage 3 Chronic Kidney Disease: a Case Report.</article-title>
            <source>J Korean Med Sci</source>
            <year>2020</year>
            <month>Sep</month>
            <day>07</day>
            <volume>35</volume>
            <issue>35</issue>
            <fpage>e293</fpage>
            <pub-id pub-id-type="pmid">32893521</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25703.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shah</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Olivero</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Gadolinium-Induced Nephrogenic Systemic Fibrosis.</article-title>
            <source>Methodist Debakey Cardiovasc J</source>
            <year>2017</year>
            <season>Jul-Sep</season>
            <volume>13</volume>
            <issue>3</issue>
            <fpage>172</fpage>
            <page-range>172-173</page-range>
            <pub-id pub-id-type="pmid">29744004</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25703.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yee</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Prophylactic Hemodialysis for Protection Against Gadolinium-Induced Nephrogenic Systemic Fibrosis: A Doll's House.</article-title>
            <source>Adv Chronic Kidney Dis</source>
            <year>2017</year>
            <month>May</month>
            <volume>24</volume>
            <issue>3</issue>
            <fpage>133</fpage>
            <page-range>133-135</page-range>
            <pub-id pub-id-type="pmid">28501073</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25703.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lange</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>M&#x00119;drzycka-D&#x00105;browska</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Zorena</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>D&#x00105;browski</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>&#x0015a;l&#x00119;zak</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Malecka-Dubiela</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rutkowski</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Nephrogenic Systemic Fibrosis as a Complication after Gadolinium-Containing Contrast Agents: A Rapid Review.</article-title>
            <source>Int J Environ Res Public Health</source>
            <year>2021</year>
            <month>Mar</month>
            <day>15</day>
            <volume>18</volume>
            <issue>6</issue>
            <pub-id pub-id-type="pmid">33804005</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25703.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gallo-Bernal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Patino-Jaramillo</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Calixto</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Higuera</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Forero</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Lara Fernandes</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>G&#x000f3;ngora</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gee</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Ghoshhajra</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Medina</surname>
                <given-names>HM</given-names>
              </name>
            </person-group>
            <article-title>Nephrogenic Systemic Fibrosis in Patients with Chronic Kidney Disease after the Use of Gadolinium-Based Contrast Agents: A Review for the Cardiovascular Imager.</article-title>
            <source>Diagnostics (Basel)</source>
            <year>2022</year>
            <month>Jul</month>
            <day>28</day>
            <volume>12</volume>
            <issue>8</issue>
            <pub-id pub-id-type="pmid">36010167</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25703.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Basak</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jesmajian</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Nephrogenic systemic fibrosis: current concepts.</article-title>
            <source>Indian J Dermatol</source>
            <year>2011</year>
            <month>Jan</month>
            <volume>56</volume>
            <issue>1</issue>
            <fpage>59</fpage>
            <page-range>59-64</page-range>
            <pub-id pub-id-type="pmid">21572795</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25703.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Golding</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Provenzale</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Nephrogenic systemic fibrosis: possible association with a predisposing infection.</article-title>
            <source>AJR Am J Roentgenol</source>
            <year>2008</year>
            <month>Apr</month>
            <volume>190</volume>
            <issue>4</issue>
            <fpage>1069</fpage>
            <page-range>1069-75</page-range>
            <pub-id pub-id-type="pmid">18356457</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25703.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Do</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Drel</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wagner</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Nephrogenic Systemic Fibrosis Is Mediated by Myeloid C-C Chemokine Receptor 2.</article-title>
            <source>J Invest Dermatol</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>139</volume>
            <issue>10</issue>
            <fpage>2134</fpage>
            <page-range>2134-2143.e2</page-range>
            <pub-id pub-id-type="pmid">30978353</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25703.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Papanicolas</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Woskie</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Jha</surname>
                <given-names>AK</given-names>
              </name>
            </person-group>
            <article-title>Health Care Spending in the United States and Other High-Income Countries.</article-title>
            <source>JAMA</source>
            <year>2018</year>
            <month>Mar</month>
            <day>13</day>
            <volume>319</volume>
            <issue>10</issue>
            <fpage>1024</fpage>
            <page-range>1024-1039</page-range>
            <pub-id pub-id-type="pmid">29536101</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25703.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Daftari Besheli</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Aran</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shaqdan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kay</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Abujudeh</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Current status of nephrogenic systemic fibrosis.</article-title>
            <source>Clin Radiol</source>
            <year>2014</year>
            <month>Jul</month>
            <volume>69</volume>
            <issue>7</issue>
            <fpage>661</fpage>
            <page-range>661-8</page-range>
            <pub-id pub-id-type="pmid">24582176</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25703.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perez-Rodriguez</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lai</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ehst</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Fine</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Bluemke</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment--report of 33 cases.</article-title>
            <source>Radiology</source>
            <year>2009</year>
            <month>Feb</month>
            <volume>250</volume>
            <issue>2</issue>
            <fpage>371</fpage>
            <page-range>371-7</page-range>
            <pub-id pub-id-type="pmid">19188312</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25703.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Woolen</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Shankar</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Gagnier</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>MacEachern</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Singer</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Davenport</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis.</article-title>
            <source>JAMA Intern Med</source>
            <year>2020</year>
            <month>Feb</month>
            <day>01</day>
            <volume>180</volume>
            <issue>2</issue>
            <fpage>223</fpage>
            <page-range>223-230</page-range>
            <pub-id pub-id-type="pmid">31816007</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25703.r19">
          <label>19</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Goldstein</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Lunyera</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mohottige</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Amrhein</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Alexopoulos</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Cameron</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Sagalla</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Crowley</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Dietch</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Kosinski</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Cantrell</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Williams Jr</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Gierisch</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <source>Risk of Nephrogenic Systemic Fibrosis after Exposure to Newer Gadolinium Agents [Internet]</source>
            <publisher-name>Department of Veterans Affairs (US)</publisher-name>
            <publisher-loc>Washington (DC)</publisher-loc>
            <year>2019</year>
            <month>10</month>
            <pub-id pub-id-type="pmid">32687278</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25703.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McNeill</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Barr</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Scleromyxedema-like fibromucinosis in a patient undergoing hemodialysis.</article-title>
            <source>Int J Dermatol</source>
            <year>2002</year>
            <month>Jun</month>
            <volume>41</volume>
            <issue>6</issue>
            <fpage>364</fpage>
            <page-range>364-7</page-range>
            <pub-id pub-id-type="pmid">12100695</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25703.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mackay-Wiggan</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Hardy</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Knobler</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Grossman</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease).</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2003</year>
            <month>Jan</month>
            <volume>48</volume>
            <issue>1</issue>
            <fpage>55</fpage>
            <page-range>55-60</page-range>
            <pub-id pub-id-type="pmid">12522371</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25703.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bernstein</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Isakova</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sullivan</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Chibnik</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Wolf</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kay</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Nephrogenic systemic fibrosis is associated with hypophosphataemia: a case-control study.</article-title>
            <source>Rheumatology (Oxford)</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>53</volume>
            <issue>9</issue>
            <fpage>1613</fpage>
            <page-range>1613-7</page-range>
            <pub-id pub-id-type="pmid">24706993</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25703.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ruiz-Genao</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Pascual-Lopez</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Fraga</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Arag&#x000fc;&#x000e9;s</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Garcia-Diez</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Osseous metaplasia in the setting of nephrogenic fibrosing dermopathy.</article-title>
            <source>J Cutan Pathol</source>
            <year>2005</year>
            <month>Feb</month>
            <volume>32</volume>
            <issue>2</issue>
            <fpage>172</fpage>
            <page-range>172-5</page-range>
            <pub-id pub-id-type="pmid">15606678</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25703.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hubbard</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Davenport</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jarmulowicz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rustin</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Scleromyxoedema-like changes in four renal dialysis patients.</article-title>
            <source>Br J Dermatol</source>
            <year>2003</year>
            <month>Mar</month>
            <volume>148</volume>
            <issue>3</issue>
            <fpage>563</fpage>
            <page-range>563-8</page-range>
            <pub-id pub-id-type="pmid">12653751</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25703.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yoldez</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ahlem</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Abderrahim</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Faten</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Soumaya</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>[Nephrogenic fibrosing dermatosis: From clinic to microscopy].</article-title>
            <source>Nephrol Ther</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>47</fpage>
            <page-range>47-49</page-range>
            <pub-id pub-id-type="pmid">29239786</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25703.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boyd</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Zic</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Abraham</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Gadolinium deposition in nephrogenic fibrosing dermopathy.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2007</year>
            <month>Jan</month>
            <volume>56</volume>
            <issue>1</issue>
            <fpage>27</fpage>
            <page-range>27-30</page-range>
            <pub-id pub-id-type="pmid">17109993</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25703.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bangsgaard</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Marckmann</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rossen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Skov</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Nephrogenic systemic fibrosis: late skin manifestations.</article-title>
            <source>Arch Dermatol</source>
            <year>2009</year>
            <month>Feb</month>
            <volume>145</volume>
            <issue>2</issue>
            <fpage>183</fpage>
            <page-range>183-7</page-range>
            <pub-id pub-id-type="pmid">19221265</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25703.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Edwards</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Laumann</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Nardone</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>FH</given-names>
              </name>
              <name>
                <surname>Restaino</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Raisch</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>McKoy</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Hammel</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Bhatt</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bauer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Samaras</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Fisher</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Bull</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Saddleton</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Belknap</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Thomsen</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Kanal</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cowper</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Abu Alfa</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>West</surname>
                <given-names>DP</given-names>
              </name>
            </person-group>
            <article-title>Advancing pharmacovigilance through academic-legal collaboration: the case of gadolinium-based contrast agents and nephrogenic systemic fibrosis-a Research on Adverse Drug Events and Reports (RADAR) report.</article-title>
            <source>Br J Radiol</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>87</volume>
            <issue>1042</issue>
            <fpage>20140307</fpage>
            <pub-id pub-id-type="pmid">25230161</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25703.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Larson</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Gagnon</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Darling</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Patterson</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Cropley</surname>
                <given-names>TG</given-names>
              </name>
            </person-group>
            <article-title>Nephrogenic Systemic Fibrosis Manifesting a Decade After Exposure to Gadolinium.</article-title>
            <source>JAMA Dermatol</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>151</volume>
            <issue>10</issue>
            <fpage>1117</fpage>
            <page-range>1117-20</page-range>
            <pub-id pub-id-type="pmid">26017458</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25703.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levine</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Elman</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Bird</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Lavi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Stolzenberg</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>McGarvey</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Asbury</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Jimenez</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Involvement of skeletal muscle in dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy).</article-title>
            <source>Muscle Nerve</source>
            <year>2004</year>
            <month>Nov</month>
            <volume>30</volume>
            <issue>5</issue>
            <fpage>569</fpage>
            <page-range>569-77</page-range>
            <pub-id pub-id-type="pmid">15389718</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25703.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Madke</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Khopkar</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Nephrogenic systemic fibrosis.</article-title>
            <source>Indian Dermatol Online J</source>
            <year>2011</year>
            <month>Jul</month>
            <volume>2</volume>
            <issue>2</issue>
            <fpage>51</fpage>
            <page-range>51-6</page-range>
            <pub-id pub-id-type="pmid">23130224</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25703.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kanal</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Patton</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Krefting</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Nephrogenic Systemic Fibrosis Risk Assessment and Skin Biopsy Quantification in Patients with Renal Disease following Gadobenate Contrast Administration.</article-title>
            <source>AJNR Am J Neuroradiol</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>41</volume>
            <issue>3</issue>
            <fpage>393</fpage>
            <page-range>393-399</page-range>
            <pub-id pub-id-type="pmid">32115422</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25703.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Attari</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Elmholdt</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Prince</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>A Systematic Review of 639 Patients with Biopsy-confirmed Nephrogenic Systemic Fibrosis.</article-title>
            <source>Radiology</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>292</volume>
            <issue>2</issue>
            <fpage>376</fpage>
            <page-range>376-386</page-range>
            <pub-id pub-id-type="pmid">31264946</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25703.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Farooqi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mumtaz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Arif</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Butt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kanor</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Memoh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Qamar</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Yosufi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The Clinical Manifestations and Efficacy of Different Treatments Used for Nephrogenic Systemic Fibrosis: A Systematic Review.</article-title>
            <source>Int J Nephrol Renovasc Dis</source>
            <year>2023</year>
            <volume>16</volume>
            <fpage>17</fpage>
            <page-range>17-30</page-range>
            <pub-id pub-id-type="pmid">36660606</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25703.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schmook</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Budde</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ulrich</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Neumayer</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Fritsche</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Stockfleth</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Successful treatment of nephrogenic fibrosing dermopathy in a kidney transplant recipient with photodynamic therapy.</article-title>
            <source>Nephrol Dial Transplant</source>
            <year>2005</year>
            <month>Jan</month>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>220</fpage>
            <page-range>220-2</page-range>
            <pub-id pub-id-type="pmid">15632355</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25703.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kafi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fisher</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Quan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Voorhees</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>UV-A1 phototherapy improves nephrogenic fibrosing dermopathy.</article-title>
            <source>Arch Dermatol</source>
            <year>2004</year>
            <month>Nov</month>
            <volume>140</volume>
            <issue>11</issue>
            <fpage>1322</fpage>
            <page-range>1322-4</page-range>
            <pub-id pub-id-type="pmid">15545539</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25703.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wahba</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Simpson</surname>
                <given-names>EL</given-names>
              </name>
            </person-group>
            <article-title>The case for ultraviolet light therapy in nephrogenic fibrosing dermopathy--report of two cases and review of the literature.</article-title>
            <source>Nephrol Dial Transplant</source>
            <year>2007</year>
            <month>Feb</month>
            <volume>22</volume>
            <issue>2</issue>
            <fpage>631</fpage>
            <page-range>631-6</page-range>
            <pub-id pub-id-type="pmid">17124282</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25703.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arora</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Setia</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Extracorporeal photopheresis: Review of technical aspects.</article-title>
            <source>Asian J Transfus Sci</source>
            <year>2017</year>
            <season>Jul-Dec</season>
            <volume>11</volume>
            <issue>2</issue>
            <fpage>81</fpage>
            <page-range>81-86</page-range>
            <pub-id pub-id-type="pmid">28970672</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25703.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Terhaar</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Saleem</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yusuf</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Extracorporeal Photopheresis in Dermatological Diseases.</article-title>
            <source>Int J Mol Sci</source>
            <year>2024</year>
            <month>Mar</month>
            <day>05</day>
            <volume>25</volume>
            <issue>5</issue>
            <pub-id pub-id-type="pmid">38474257</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25703.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rose</surname>
                <given-names>WN</given-names>
              </name>
            </person-group>
            <article-title>Photopheresis Provides Significant Long-Lasting Benefit in Nephrogenic Systemic Fibrosis.</article-title>
            <source>Case Rep Dermatol Med</source>
            <year>2017</year>
            <volume>2017</volume>
            <fpage>3240287</fpage>
            <pub-id pub-id-type="pmid">28695022</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25703.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Swaminathan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Arbiser</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Hiatt</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>High</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Abul-Ezz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Horn</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>SV</given-names>
              </name>
            </person-group>
            <article-title>Rapid improvement of nephrogenic systemic fibrosis with rapamycin therapy: possible role of phospho-70-ribosomal-S6 kinase.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2010</year>
            <month>Feb</month>
            <volume>62</volume>
            <issue>2</issue>
            <fpage>343</fpage>
            <page-range>343-5</page-range>
            <pub-id pub-id-type="pmid">20115955</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25703.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kowal-Bielecka</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Fransen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Avouac</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kulak</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Allanore</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Distler</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Clements</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cutolo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Czirjak</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Damjanov</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Del Galdo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Denton</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Distler</surname>
                <given-names>JHW</given-names>
              </name>
              <name>
                <surname>Foeldvari</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Figelstone</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Frerix</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Furst</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Guiducci</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hunzelmann</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Khanna</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Matucci-Cerinic</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Herrick</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>van den Hoogen</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>van Laar</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Riemekasten</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Silver</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Sulli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tarner</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Tyndall</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Welling</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wigley</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Valentini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>UA</given-names>
              </name>
              <name>
                <surname>Zulian</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller-Ladner</surname>
                <given-names>U</given-names>
              </name>
              <collab>EUSTAR Coauthors</collab>
            </person-group>
            <article-title>Update of EULAR recommendations for the treatment of systemic sclerosis.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>76</volume>
            <issue>8</issue>
            <fpage>1327</fpage>
            <page-range>1327-1339</page-range>
            <pub-id pub-id-type="pmid">27941129</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25703.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elmholdt</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Buus</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>Ramsing</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Olesen</surname>
                <given-names>AB</given-names>
              </name>
            </person-group>
            <article-title>Antifibrotic effect after low-dose imatinib mesylate treatment in patients with nephrogenic systemic fibrosis: an open-label non-randomized, uncontrolled clinical trial.</article-title>
            <source>J Eur Acad Dermatol Venereol</source>
            <year>2013</year>
            <month>Jun</month>
            <volume>27</volume>
            <issue>6</issue>
            <fpage>779</fpage>
            <page-range>779-84</page-range>
            <pub-id pub-id-type="pmid">22188390</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25703.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yerram</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Saab</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Karuparthi</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Hayden</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Khanna</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Nephrogenic systemic fibrosis: a mysterious disease in patients with renal failure--role of gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2007</year>
            <month>Mar</month>
            <volume>2</volume>
            <issue>2</issue>
            <fpage>258</fpage>
            <page-range>258-63</page-range>
            <pub-id pub-id-type="pmid">17699422</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25703.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chung</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>KY</given-names>
              </name>
            </person-group>
            <article-title>Nephrogenic fibrosing dermopathy: response to high-dose intravenous immunoglobulin.</article-title>
            <source>Br J Dermatol</source>
            <year>2004</year>
            <month>Mar</month>
            <volume>150</volume>
            <issue>3</issue>
            <fpage>596</fpage>
            <page-range>596-7</page-range>
            <pub-id pub-id-type="pmid">15030351</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25703.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Panesar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yacoub</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>What is the role of renal transplantation in a patient with nephrogenic systemic fibrosis?</article-title>
            <source>Semin Dial</source>
            <year>2011</year>
            <season>Jul-Aug</season>
            <volume>24</volume>
            <issue>4</issue>
            <fpage>373</fpage>
            <page-range>373-4</page-range>
            <pub-id pub-id-type="pmid">21851392</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25703.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cuffy</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Formica</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Simmons</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Abu Alfa</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Carlson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Girardi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cowper</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Kulkarni</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Renal transplantation for nephrogenic systemic fibrosis: a case report and review of the literature.</article-title>
            <source>Nephrol Dial Transplant</source>
            <year>2011</year>
            <month>Mar</month>
            <volume>26</volume>
            <issue>3</issue>
            <fpage>1099</fpage>
            <page-range>1099-101</page-range>
            <pub-id pub-id-type="pmid">21079195</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25703.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Panesar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Banerjee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Barone</surname>
                <given-names>GW</given-names>
              </name>
            </person-group>
            <article-title>Clinical improvement of nephrogenic systemic fibrosis after kidney transplantation.</article-title>
            <source>Clin Transplant</source>
            <year>2008</year>
            <season>Nov-Dec</season>
            <volume>22</volume>
            <issue>6</issue>
            <fpage>803</fpage>
            <page-range>803-8</page-range>
            <pub-id pub-id-type="pmid">18713261</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25703.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wagner</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Drel</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gorin</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Pathophysiology of gadolinium-associated systemic fibrosis.</article-title>
            <source>Am J Physiol Renal Physiol</source>
            <year>2016</year>
            <month>Jul</month>
            <day>01</day>
            <volume>311</volume>
            <issue>1</issue>
            <fpage>F1</fpage>
            <page-range>F1-F11</page-range>
            <pub-id pub-id-type="pmid">27147669</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25703.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Todd</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Kagan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chibnik</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Kay</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure.</article-title>
            <source>Arthritis Rheum</source>
            <year>2007</year>
            <month>Oct</month>
            <volume>56</volume>
            <issue>10</issue>
            <fpage>3433</fpage>
            <page-range>3433-41</page-range>
            <pub-id pub-id-type="pmid">17907148</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25703.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>He</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kwatra</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Zampella</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Loss</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Nephrogenic systemic fibrosis: fibrotic plaques and contracture following exposure to gadolinium-based contrast media.</article-title>
            <source>BMJ Case Rep</source>
            <year>2016</year>
            <month>Apr</month>
            <day>12</day>
            <volume>2016</volume>
            <pub-id pub-id-type="pmid">27073153</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25703.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maripuri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Johansen</surname>
                <given-names>KL</given-names>
              </name>
            </person-group>
            <article-title>Risk of Gadolinium-Based Contrast Agents in Chronic Kidney Disease-Is Zero Good Enough?</article-title>
            <source>JAMA Intern Med</source>
            <year>2020</year>
            <month>Feb</month>
            <day>01</day>
            <volume>180</volume>
            <issue>2</issue>
            <fpage>230</fpage>
            <page-range>230-232</page-range>
            <pub-id pub-id-type="pmid">31816006</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25703.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mehdi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Taliercio</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Nakhoul</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Contrast media in patients with kidney disease: An update.</article-title>
            <source>Cleve Clin J Med</source>
            <year>2020</year>
            <month>Nov</month>
            <day>02</day>
            <volume>87</volume>
            <issue>11</issue>
            <fpage>683</fpage>
            <page-range>683-694</page-range>
            <pub-id pub-id-type="pmid">33139262</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
